Inhibition of RANK/RANKL signal transduction pathway: A promising approach for osteoporosis treatment
- 31 August 2008
- journal article
- Published by Elsevier BV in Medical Hypotheses
- Vol. 71 (2), 256-258
- https://doi.org/10.1016/j.mehy.2008.03.021
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- RANK ligandThe International Journal of Biochemistry & Cell Biology, 2007
- The Role of Receptor Activator of Nuclear Factor-κB (RANK)/RANK Ligand/Osteoprotegerin: Clinical ImplicationsJournal of Clinical Endocrinology & Metabolism, 2007
- Clinical development of anti-RANKL therapyArthritis Research & Therapy, 2007
- RANKing Intracellular Signaling in OsteoclastsIUBMB Life, 2005
- Regulatory mechanisms of osteoblast and osteoclast differentiationOral Diseases, 2002
- Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysisNature Genetics, 2000
- The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone ResorptionJournal of Bone and Mineral Research, 2000
- Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligandProceedings of the National Academy of Sciences of the United States of America, 1999
- OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesisNature, 1999
- Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKLProceedings of the National Academy of Sciences of the United States of America, 1998